AI English summary of an SEC filing — figures as filed
Waters WATThe company said the Board of Directors increased the size of the Board from 9 to 10 members on August 13, 2024 and appointed Heather Knight as a director effective August 14, 2024 to fill the resulting vacancy. Her term runs until the 2025 annual meeting of stockholders.
Key points
AI summaryThe company said the Board of Directors increased the size of the Board from 9 to 10 members on August 13, 2024 and appointed Heather Knight as a director effective August 14, 2024 to fill the resulting vacancy. Her term runs until the 2025 annual meeting of stockholders.
The company said its board determined that Knight meets the New York Stock Exchange corporate governance listing standards for independence. The press release described her as currently serving as Executive Vice President and Group President, Medical Products and Therapies at Baxter International, with nearly 30 years of experience.
Waters said Knight will receive an initial equity award valued at $91,666, consisting of 50% in restricted stock and 50% in non-qualified stock options, both vesting on the 1st anniversary of the grant date. Her prorated cash retainer through the 2025 annual meeting is $54,130.
The company said it issued a press release on August 14, 2024 announcing Knight's appointment to the board. Board Chair Dr. Flemming Ornskov said her experience complements the diverse skills and backgrounds of board members, and Dr. Udit Batra, President and CEO, also welcomed her to the board.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Board Expansion and Appointment of Heather Knight
The company said the Board of Directors increased the size of the Board from 9 to 10 members on August 13, 2024 and appointed Heather Knight as a director effective August 14, 2024 to fill the resulting vacancy. Her term runs until the 2025 annual meeting of stockholders.
Source · Based on the filing body and exhibits
Independence Determination and Knight's Background
The company said its board determined that Knight meets the New York Stock Exchange corporate governance listing standards for independence. The press release described her as currently serving as Executive Vice President and Group President, Medical Products and Therapies at Baxter International, with nearly 30 years of experience.
Source · Based on the filing body and exhibits
Knight's Initial Equity Award and Cash Retainer
Waters said Knight will receive an initial equity award valued at $91,666, consisting of 50% in restricted stock and 50% in non-qualified stock options, both vesting on the 1st anniversary of the grant date. Her prorated cash retainer through the 2025 annual meeting is $54,130.
Source · Based on the filing body and exhibits
Appointment Press Release and Statements
The company said it issued a press release on August 14, 2024 announcing Knight's appointment to the board. Board Chair Dr. Flemming Ornskov said her experience complements the diverse skills and backgrounds of board members, and Dr. Udit Batra, President and CEO, also welcomed her to the board.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…